Prostate cancer, presents a high incidence worldwide and represents the second cause of cancer related deaths in men, after lung cancer. At present, the only noninvasive procedure used for prostate cancer early diagnosis is the measurement of serum prostate-specific antigen in blood. Since its introduction in 1982, it has been demonstrated that the mortality due to prostate cancer has been reduced. But, recently the use of serum PSA has been questioned because it has a low accuracy, especially regarding the specificity. In prostate cancer, new noninvasive diagnostic approaches are needed to replace the standard techniques. Molecular biomarkers has been demonstrated that play an important role in the diagnostic of some cancer types such as lung cancer, colon cancer, bladder cancer, and breast cancer and prostate cancer. Recently, a number of studies have shown the usefulness of molecular biomarkers in the early diagnosis and recurrence prediction in prostate cancer patients.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Prostate cancer, presents a high incidence worldwide and represents the second cause of cancer related deaths in men, after lung cancer. At present, the only noninvasive procedure used for prostate cancer early diagnosis is the measurement of serum prostate-specific antigen in blood. Since its introduction in 1982, it has been demonstrated that the mortality due to prostate cancer has been reduced. But, recently the use of serum PSA has been questioned because it has a low accuracy, especially regarding the specificity. In prostate cancer, new noninvasive diagnostic approaches are needed to replace the standard techniques. Molecular biomarkers has been demonstrated that play an important role in the diagnostic of some cancer types such as lung cancer, colon cancer, bladder cancer, and breast cancer and prostate cancer. Recently, a number of studies have shown the usefulness of molecular biomarkers in the early diagnosis and recurrence prediction in prostate cancer patients.
Raluca Dumache M.D., Ph.D., Lecturer, ”Victor Babes” University of Medicine and Pharmacy Timisoara, Romania. Alexandru Florin Rogobete, M.Sc., Researcher, Emergency County Hospital ”Pius Brinzeu” Timisoara, Romania. Radu Traian Minciu M.D., Ph.D., Lecturer, ”Victor Babes” University of Medicine and Pharmacy Timisoara, Romania.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Prostate cancer, presents a high incidence worldwide and represents the second cause of cancer related deaths in men, after lung cancer. At present, the only noninvasive procedure used for prostate cancer early diagnosis is the measurement of serum prostate-specific antigen in blood. Since its introduction in 1982, it has been demonstrated that the mortality due to prostate cancer has been reduced. But, recently the use of serum PSA has been questioned because it has a low accuracy, especially regarding the specificity. In prostate cancer, new noninvasive diagnostic approaches are needed to replace the standard techniques. Molecular biomarkers has been demonstrated that play an important role in the diagnostic of some cancer types such as lung cancer, colon cancer, bladder cancer, and breast cancer and prostate cancer. Recently, a number of studies have shown the usefulness of molecular biomarkers in the early diagnosis and recurrence prediction in prostate cancer patients. 52 pp. Englisch. N° de réf. du vendeur 9783659872976
Quantité disponible : 2 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Prostate cancer, presents a high incidence worldwide and represents the second cause of cancer related deaths in men, after lung cancer. At present, the only noninvasive procedure used for prostate cancer early diagnosis is the measurement of serum prostate-specific antigen in blood. Since its introduction in 1982, it has been demonstrated that the mortality due to prostate cancer has been reduced. But, recently the use of serum PSA has been questioned because it has a low accuracy, especially regarding the specificity. In prostate cancer, new noninvasive diagnostic approaches are needed to replace the standard techniques. Molecular biomarkers has been demonstrated that play an important role in the diagnostic of some cancer types such as lung cancer, colon cancer, bladder cancer, and breast cancer and prostate cancer. Recently, a number of studies have shown the usefulness of molecular biomarkers in the early diagnosis and recurrence prediction in prostate cancer patients. N° de réf. du vendeur 9783659872976
Quantité disponible : 1 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 52 pages. 8.66x5.91x0.12 inches. In Stock. N° de réf. du vendeur 3659872970
Quantité disponible : 1 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. N° de réf. du vendeur 159146750
Quantité disponible : Plus de 20 disponibles
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Prostate cancer, presents a high incidence worldwide and represents the second cause of cancer related deaths in men, after lung cancer. At present, the only noninvasive procedure used for prostate cancer early diagnosis is the measurement of serum prostate-specific antigen in blood. Since its introduction in 1982, it has been demonstrated that the mortality due to prostate cancer has been reduced. But, recently the use of serum PSA has been questioned because it has a low accuracy, especially regarding the specificity. In prostate cancer, new noninvasive diagnostic approaches are needed to replace the standard techniques. Molecular biomarkers has been demonstrated that play an important role in the diagnostic of some cancer types such as lung cancer, colon cancer, bladder cancer, and breast cancer and prostate cancer. Recently, a number of studies have shown the usefulness of molecular biomarkers in the early diagnosis and recurrence prediction in prostate cancer patients.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 52 pp. Englisch. N° de réf. du vendeur 9783659872976
Quantité disponible : 1 disponible(s)